Cardiologists are increasingly prescribing GLP-1 receptor agonists to reduce major adverse cardiovascular events (MACE) in non-diabetic patients. Multi-center trials demonstrate risk reductions that extend beyond simple weight management metrics.
Insurance Coverage and Manufacturing Capacity
Payer coverage for cardiovascular indications expanded by 18% following updated clinical guidelines from national health authorities. However, supply chain constraints on active pharmaceutical ingredients continue to limit patient access, prompting pharmaceutical producers to invest billions in specialized sterile fill-finish infrastructure.